Full-Time

Field Reimbursement Manager

Confirmed live in the last 24 hours

argenx

argenx

1,001-5,000 employees

Biotechnology for autoimmune diseases and cancer

No salary listed

Senior, Expert

New York, NY, USA

Candidates should be based in or around New York City.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Customer Service
Requirements
  • Minimum of 7 years in the Bio-Pharma industry
  • Minimum of 4 years reimbursement specific experience
  • Exceptional billing and coding experience with CMS 1500/UB-04 forms required
  • Strong pharmaceutical and reimbursement experience with Specialty Pharmacy, Buy and Bill, and Medical/Pharmacy Benefit experience supporting specialty products
  • Must have Medicare and commercial insurance coverage experience (limited networks a plus)
  • Must be able to deliver and document benefit investigation outcomes and relay status reports on a regular basis
  • Strong customer service experience
  • Proven presentation skills and experience
  • Bachelor’s degree required
Responsibilities
  • Provide on-demand education (including Lunch and Learns or Dinner presentations) for the office staff regarding Reimbursement and support services that are available through argenx
  • Office interaction will include education and reimbursement support both in-person and virtually
  • Educate on Benefit Investigation, Prior Authorization Process, Support Center Services, Medicare and Commercial coverage and patient communication streams
  • Monthly activity reporting captures educational topics at FRM level
  • Provide offices with Product Distribution and Ordering Support and Site of Care Assistance which consists of determining the most appropriate site of care based on the patient’s payer preferences and available benefits
  • Reimbursement Support on Case management, billing and coding updates, appropriate claims submission, Specialty Pharmacy, Medical Benefit Interpretation, understanding medical necessity, claims and appeal assistance, information related to co-pay assistance and patient assistance programs
  • FRM will collaborate with case manager and case coordinator on average of 4 x month and ad hoc as needed for escalations, these interactions are tracked in FRM CRM and hub system
  • Coordinate with HCP and staff to obtain and provide patient and provider specific information
  • Provide Aging Case Assistance thorough collaboration with cross functional partners (Case Coordinators, Case Managers, and Regional Account Directors) in order to advance open case referrals. All FRM interactions/activities are tracked in FRM CRM which are reportable to leadership
  • Territory performance will be monitored via FRM CRM dashboard daily, trending results will be identified through quarterly reporting
  • Collaborate with cross-functional partners on overall account and territory strategy to maximize internal/external customer knowledge on payor policy and processes
  • Proactive and reactive managing through conflict; navigate complexity of accounts and patient journey
Desired Qualifications
  • Neurology experience a plus
  • Experience in the healthcare industry including, but not limited to insurance verification, prior authorizations, and/or claim adjudication, billing and coding
  • Educating on use of miscellaneous J Code and Modifiers for wastage

argenx develops immunology solutions aimed at treating severe autoimmune diseases and cancer. The company focuses on creating therapeutic antibodies, with a notable product being cusatuzumab, which is in development for treating blood cancers like leukemia in collaboration with Janssen R&D. argenx stands out from competitors by emphasizing partnerships with academic institutions and industry players to turn scientific research into viable treatments. The company's goal is to advance its research and development efforts, leading to successful licensing agreements and collaborations that facilitate the commercialization of its products.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Ghent, Belgium

Founded

2008

Simplify Jobs

Simplify's Take

What believers are saying

  • Positive CHMP opinion for VYVGART in CIDP could capture significant European market share.
  • Phase 2 trial of cusatuzumab in AML enhances argenx's oncology pipeline.
  • FDA priority review for VYVGART Hytrulo indicates potential accelerated U.S. market entry.

What critics are saying

  • Increased competition in autoimmune disease treatment could impact argenx's market share.
  • Potential delays in clinical trial timelines due to regulatory changes in key markets.
  • Dependence on key partnerships poses risk if collaborations face challenges or termination.

What makes argenx unique

  • Argenx focuses on innovative immunology solutions for autoimmune diseases and cancer.
  • The company collaborates with academic institutions and industry partners for therapeutic antibody development.
  • Cusatuzumab, developed with Janssen R&D, targets hematological malignancies like leukemia.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

0%
PharmiWeb
May 1st, 2025
Argenx Announces Positive Chmp Opinion For Vyvgart (Efgartigimod Alfa) Subcutaneous Injection For Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

VYVGART ® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trialEuropean Commission (EC) decision on marketing authorization application (MAA) expected within approximately two monthsAmsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended European Commission (EC) approval of VYVGART® 1000mg (efgartigimod alfa) for subcutaneous (SC) injection as a monotherapy for the treatment of adult patients with progressive or relapsing active chronic inflammatory demyelinating polyneuropathy (CIDP) after prior treatment with corticosteroids or immunoglobulins.“Our mission is to develop innovative, targeted treatments for patients with rare and severe autoimmune diseases, who continue to face significant unmet needs. The positive CHMP opinion for VYVGART in CIDP brings us one step closer to providing patients across Europe with a transformational new treatment option that provides meaningful functional improvement,” said Luc Truyen M.D., Ph.D., Chief Medical Officer, argenx. “VYVGART is the first and only targeted IgG Fc-antibody fragment for CIDP and if approved, would mark the first treatment in Europe with a novel, precision mechanism of action for CIDP patients in 30 years.”VYVGART for subcutaneous injection is available as a vial or prefilled syringe and can be administered by a patient, caregiver, or healthcare professional. Treatment is initiated with a weekly dose regimen and may be adjusted to every other week based on clinical evaluation.The CHMP recommendation is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date. In the ADHERE study, 66.5% (214/322) of patients treated with VYVGART, regardless of prior treatment, demonstrated evidence of clinical improvement, including improvements in mobility, function and strength. ADHERE met its primary endpoint (p<0.0001) demonstrating a 61% reduction (HR: 0.39 95% CI: 0.25; 0.61) in the risk of relapse versus placebo

Stock Titan
Feb 25th, 2025
argenx to Present at TD Cowen 45th Annual Healthcare Conference

argenx, a global immunology company focused on improving lives of people with severe autoimmune diseases, has announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the TD Cowen 45th Annual Healthcare Conference.

Business Wire
Nov 22nd, 2024
OncoVerity Secures Extended Series A to Advance Cusatuzumab in Newly Diagnosed AML

Alongside financing, first patients dosed in OV-AML-1231, a Phase 2 randomized controlled trial of cusatuzumab in newly diagnosed AML

Clinical Trial Vanguard
Nov 20th, 2024
Steritas & Argenx Announce Collaboration to Advance Steroid-Sparing Therapeutics

Steritas LLC, a company focused on improving care for patients treated with steroids, has partnered with global immunology company Argenx.

BioSpace
May 9th, 2024
Argenx Reports First Quarter 2024 Financial Results And Provides Business Update

$398 million in first quarter global net product sales. FDA review ongoing for CIDP sBLA with PDUFA target action date of June 21, 2024. On track to submit filing for pre-filled syringe (PFS) in second quarter 2024